Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Avalo Therapeutics Inc (AVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: AVTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $30.86
1 Year Target Price $30.86
| 6 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -88.05% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 140.14M USD | Price to earnings Ratio 1.63 | 1Y Target Price 30.86 |
Price to earnings Ratio 1.63 | 1Y Target Price 30.86 | ||
Volume (30-day avg) 8 | Beta 0.89 | 52 Weeks Range 3.39 - 16.00 | Updated Date 09/15/2025 |
52 Weeks Range 3.39 - 16.00 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -13640.59% |
Management Effectiveness
Return on Assets (TTM) -32.01% | Return on Equity (TTM) -90.25% |
Valuation
Trailing PE 1.63 | Forward PE - | Enterprise Value 27555353 | Price to Sales(TTM) 317.78 |
Enterprise Value 27555353 | Price to Sales(TTM) 317.78 | ||
Enterprise Value to Revenue 62.48 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 13152400 | Shares Floating 6954308 |
Shares Outstanding 13152400 | Shares Floating 6954308 | ||
Percent Insiders 5.26 | Percent Institutions 64.11 |
Upturn AI SWOT
Avalo Therapeutics Inc
Company Overview
History and Background
Avalo Therapeutics, Inc. (formerly Cerecor Inc.) is a clinical-stage biopharmaceutical company. It was founded as Cerecor in 2011. The company focuses on the discovery, development, and commercialization of therapeutics for unmet medical needs, including rare genetic diseases.
Core Business Areas
- AVTX-801 (MCT8 deficiency): Development of AVTX-801 for the treatment of MCT8 deficiency, a rare X-linked genetic disorder affecting thyroid hormone transport. This is their primary and most advanced program.
- Other Research Programs: Avalo also has research programs focused on developing therapeutics for other rare diseases, though these are generally in earlier stages of development.
Leadership and Structure
Avalo's leadership team comprises individuals with experience in pharmaceutical development and commercialization. The organizational structure includes departments focused on research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- AVTX-801 (MCT8 deficiency): AVTX-801 is an investigational drug for MCT8 deficiency. The company is working toward FDA approval and is involved in clinical trials to prove its effectiveness. No market share exists, as it is not yet approved. Competitors targeting MCT8 include Ionis Pharmaceuticals.
Market Dynamics
Industry Overview
Avalo operates in the biopharmaceutical industry, specifically focusing on rare disease therapeutics. This segment is characterized by high unmet medical needs, regulatory incentives, and potential for premium pricing.
Positioning
Avalo is positioned as a developer of targeted therapies for rare genetic diseases. Its competitive advantage lies in its focus on diseases with limited or no existing treatment options.
Total Addressable Market (TAM)
The MCT8 deficiency market is estimated to be worth millions USD. The company is positioned to capture a large portion, assuming successful clinical trials and FDA approvals.
Upturn SWOT Analysis
Strengths
- Focus on rare disease therapeutics
- Lead asset (AVTX-801) in clinical development
- Experienced management team
- Orphan drug designation potential
Weaknesses
- Limited financial resources
- Dependence on a single key asset (AVTX-801)
- High risk of clinical trial failure
- Small company size and limited infrastructure
Opportunities
- Positive clinical trial results
- FDA approval and commercialization of AVTX-801
- Expansion of pipeline through acquisitions or partnerships
- Increased awareness and diagnosis of MCT8 deficiency
Threats
- Clinical trial failure
- Regulatory hurdles
- Competition from other companies developing rare disease therapies
- Dilution of shareholder value through fundraising
Competitors and Market Share
Key Competitors
- IONS
- SRPT
- RLMD
Competitive Landscape
Avalo faces competition from established pharmaceutical companies and other biotechs focused on rare diseases. The company's success depends on demonstrating the efficacy and safety of its therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage. Growth is tied to its clinical trial advancement.
Future Projections: Future growth is contingent on successful clinical trial results and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing AVTX-801 through clinical trials and exploring partnerships.
Summary
Avalo Therapeutics is a high-risk, high-reward company focusing on rare disease therapies. Its success hinges on the positive outcomes of its clinical trials, especially for AVTX-801. The company must carefully manage its resources and navigate the regulatory landscape. It will need partnerships to help continue to develop and market products once they reach approval.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made in consultation with a qualified financial advisor. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avalo Therapeutics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2015-11-13 | President, CEO & Director Dr. Garry A. Neil M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.avalotx.com |
Full time employees 23 | Website https://www.avalotx.com | ||
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.